Black Diamond Therapeutics (NASDAQ:BDTX) used a presentation at the 46th annual TD Cowen Healthcare Conference to highlight ...
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...
Solid tumors, prevalent across various systems such as the respiratory, digestive, urinary, and gynecologic systems, constitute a significant challenge in adult oncology. These tumors are ...
Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...
Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics.
The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company’s oncology pipeline Targeting a $16.2 Billion Market OpportunityLOS ANGELES--(BUSINESS ...
The FDA granted full approval encorafenib (Braftovi) in combination with cetuximab (Erbitux) and fluorouracil-based ...
Erasca (NASDAQ:ERAS) executives outlined the company’s strategy to target RAS-driven cancers and previewed upcoming clinical milestones during a fireside chat hosted by Oppenheimer oncology analyst ...
The approval comes under the National Priority Voucher Program, joining Augmentin XR as one of the few approvals from the voucher program as of February 27, 2026. Hernexeos was granted a national ...
Suchan still needed chemotherapy and radiation, but Salgia credits Rybrevant for shrinking her tumors 60 to 70%. It specifically targets her cancer cells and revs up the immune system. For a year and ...
The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...
SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb today announced that SystImmune's parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results